Co-Diagnostics Begins Clinical Testing for Respiratory Multiplex PCR Test
The company aims to support FDA 510(k) clearance submission for its point-of-care platform detecting flu A/B, COVID-19, and RSV.
Read MorePosted by CLP Edit Staff | Nov 21, 2025 | Covid 19, Flu & Respiratory Infections |
The company aims to support FDA 510(k) clearance submission for its point-of-care platform detecting flu A/B, COVID-19, and RSV.
Read MorePosted by CLP Edit Staff | Nov 19, 2025 | Company News |
The association’s incoming CEO brings more than two decades of leadership experience in global health, nonprofit management, and the scientific community.
Read MorePosted by CLP Edit Staff | Nov 14, 2025 | Infectious Diseases |
The multiplex PCR assay achieved 100% accuracy while reducing turnaround time for histoplasmosis, blastomycosis, and coccidioidomycosis diagnosis.
Read MorePosted by CLP Edit Staff | Nov 14, 2025 | Infectious Diseases |
The droplet digital PCR assay shows 90.9% sensitivity and can detect previously missed cases of the bacterial infection.
Read MorePosted by CLP Edit Staff | Nov 12, 2025 | Covid 19, Flu & Respiratory Infections |
The collaboration will provide quality assessment products to support the commercialization of a molecular point-of-care assay for COVID-19 and influenza detection.
Read More